Stimulant medication treatment of target behaviors in children with autism: A population-based study

Journal of Developmental and Behavioral Pediatrics

Volumn 29, Issue 2, 2008, Pages 75-81

  Nickels, Katherine C ^a   Katusic, Slavica K ^a   Colligan, Robert C ^a   Weaver, Amy L ^a   Voigt, Robert G ^a,b   Barbaresi, William J ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Autism; Autistic disorder; Stimulant medications

Indexed keywords

AMPHETAMINE; DEXAMPHETAMINE; METHAMPHETAMINE; METHYLPHENIDATE; PEMOLINE;

ADOLESCENT; ADULT; ANXIETY; APPETITE; ARTICLE; ATTENTION DISTURBANCE; AUTISM; BEHAVIOR DISORDER; CHILD; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DROWSINESS; DRUG USE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERACTIVITY; IMPULSIVENESS; INFANT; IRRITABILITY; LETHARGY; MAJOR CLINICAL STUDY; MALE; NEWBORN; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STOMACH PAIN; TIC; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; AUTISTIC DISORDER; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MINNESOTA; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 42149184101     PISSN: 0196206X     EISSN: None     Source Type: Journal    
DOI: 10.1097/DBP.0b013e31815f24f7     Document Type: Article

References (31)

1. Volkmar FR, Pauls D. Autism. Lancet. 2003 Oct 4;362 (9390):1133-1141.
2. Carminati GG, Deriaz N, Bertschy G. Low-dose venlafaxine in three adolescents and young adults with autistic disorder improves self-injurious behavior and attention deficit/hyperactivity disorders (ADHD)-like symptoms. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(2):312-315.
3. American Psychiatric Association. Diagnostic criteria from DSMIV-TR. 4th edition. Washington, D.C. 2000.
4. American Psychiatric Association. Diagnostic criteria from DSM-IV. Washington, D.C. 1994:65-78.
5. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62(11):1266-1274.
6. Campbell M, Schopler E, Cueva JE, Hallin A. Treatment of autistic disorder. J Am Acad Child Adolesc Psychiatry. 1996;35(2):134-143.
7. Di Martino A, Melis G, Cianchetti C, Zuddas A. Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study. J Child Adolesc Psychopharmacol. 2004;14(2):207-218.
8. McDougle CJ, Posey D. Genetics of childhood disorders: XLIV. Autism, Part 3: Psychopharmacology of autism. J Am Acad Child Adolesc Psychiatry. 2002;41(11):1380-1383.
9. Palermo MT, Curatolo P. Pharmacologic treatment of autism. J Child Neurol. 2004;19(3):155-164.
10. Rapin I. Autistic children: diagnosis and clinical features. Pediatrics. 1991;87(5 Pt 2):751-760.
11. Stigler KA, Desmond LA, Posey DJ, Wiegand RE, McDougle CJ. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2004;14(1):49-56.
12. Hattori J, Ogino T, Abiru K, Nakano K, Oka M, Ohtsuka Y. Are pervasive developmental disorders and attention-deficit/hyperactivity disorder distinct disorders? Brain Dev. 2006 Jul; 28(6):371-374. Epub 2006 Feb 28.
13. Aman MG, Van Bourgondien ME, Wolford PL, Sarphare G. Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use. J Am Acad Child Adolesc Psychiatry. 1995;34(12):1672-1681.
14. Martin A, Scahill L, Klin A, Volkmar FR. Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use. J Am Acad Child Adolesc Psychiatry. 1999;38(7):923-931.
15. Langworthy-Lam KS, Aman MG, Van Bourgondien ME. Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. J Child Adolesc Psychopharmacol. 2002;12(4):311-321.
16. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108(4):1033-1044.
17. Dulcan M. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1997;36(10 Suppl):85S-121S.
18. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ. Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr. 2006;27(1):1-10.
19. Quintana H, Birmaher B, Stedge D, et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord. 1995;25(3):283-294.
20. Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord. 2000;30(3):245-255.
21. Aman MG, Langworthy KS. Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders. J Autism Dev Disord. 2000;30(5):451-459.
22. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ. The incidence of autism in Olmsted County, Minnesota, 1976-1997: results from a population-based study. Arch Pediatr Adolesc. Med 2005;159(1):37-44.
23. Challman TD, Barbaresi WJ, Katusic SK, Weaver A. The yield of the medical evaluation of children with pervasive developmental disorders. J Autism Dev Disord. 2003;33(2):187-192.
24. Melton LJ III. History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996;71:266-274.
25. Aman MG, Lam KS, Van Bourgondien ME. Medication patterns in patients with autism: temporal, regional, and demographic influences. J Child Adolesc Psychopharmacol. 2005;15(1):116-126.
26. Greenhill LL, Swanson JM, Vitiello B, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry. 2001;40(2):180-187.
27. Handen BL, Feldman H, Gosling A, Breaux AM, McAuliffe S. Adverse side effects of methylphenidate among mentally retarded children with ADHD. J Am Acad Child Adolesc Psychiatry. 1991;30(2):241-245.
28. Aman MG, Buican B, Arnold LE. Methylphenidate treatment in children with borderline IQ and mental retardation: analysis of three aggregated studies. J Child Adolesc Psychopharmacol. 2003;13(1):29-40.
29. Handen BL, Breaux AM, Gosling A, Ploof DL, Feldman H. Efficacy of methylphenidate among mentally retarded children with attention deficit hyperactivity disorder. Pediatrics. 1990;86(6):922-930.
30. Handen BL, Feldman HM, Lurier A, Murray PJ. Efficacy of methylphenidate among preschool children with developmental disabilities and ADHD. J Am Acad Child Adolesc Psychiatry. 1999;38(7):805-812.
31. Pearson DA, Santos CW, Roache JD, et al. Treatment effects of methylphenidate on behavioral adjustment in children with mental retardation and ADHD. J Am Acad Child Adolesc Psychiatry. 2003;42(2):209-216.